GLABF (Gemina Laboratories) ROE % Adjusted to Book Value: 0.00% (As of Oct. 2025)


What is Gemina Laboratories ROE % Adjusted to Book Value?

Gemina Laboratories GLABF -27.59% ROE % Adjusted to Book Value is 0.00% as of Oct. 2025. The stock has 2 warning signs investors should review.

Gemina Laboratories's ROE % for the quarter that ended in Oct. 2025 was 0.00%. Gemina Laboratories's PB Ratio for the quarter that ended in Oct. 2025 was N/A. Gemina Laboratories's ROE % Adjusted to Book Value for the quarter that ended in Oct. 2025 was N/A.

Gemina Laboratories ROE % Adjusted to Book Value Related Terms

Gemina Laboratories ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories ROE % Adjusted to Book Value Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
ROE % Adjusted to Book Value
0.00 0.00 0.00 0.00 0.00

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GLABF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Gemina Laboratories's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gemina Laboratories ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's ROE % Adjusted to Book Value falls into.


Gemina Laboratories ROE % Adjusted to Book Value Calculation

Gemina Laboratories's ROE % Adjusted to Book Value for the fiscal year that ended in Jan. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Gemina Laboratories's ROE % Adjusted to Book Value for the quarter that ended in Oct. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Gemina Laboratories (GLABF) has a ROE % Adjusted to Book Value of 0.00% as of Oct. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Gemina Laboratories and its competitors.
Is Gemina Laboratories' ROE % Adjusted to Book Value too high?
Gemina Laboratories' current ROE % Adjusted to Book Value is 0.00%.
How does Gemina Laboratories' ROE % Adjusted to Book Value compare to VRTX and REGN?
Gemina Laboratories' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Gemina Laboratories and its competitors. Gemina Laboratories's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current ROE % Adjusted to Book Value is 0.00% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.